5.94
0.29 (5.13%)
| Previous Close | 5.65 |
| Open | 5.69 |
| Volume | 364,986 |
| Avg. Volume (3M) | 1,345,862 |
| Market Cap | 453,716,768 |
| Price / Earnings (TTM) | 297.00 |
| Price / Earnings (Forward) | 45.45 |
| Price / Sales | 4.93 |
| Price / Book | 13.16 |
| 52 Weeks Range | |
| Earnings Date | 4 Mar 2025 - 10 Mar 2025 |
| Profit Margin | 1.62% |
| Operating Margin (TTM) | 6.26% |
| Diluted EPS (TTM) | 0.020 |
| Quarterly Revenue Growth (YOY) | 31.20% |
| Total Debt/Equity (MRQ) | 8.42% |
| Current Ratio (MRQ) | 2.95 |
| Operating Cash Flow (TTM) | 4.17 M |
| Levered Free Cash Flow (TTM) | 4.38 M |
| Return on Assets (TTM) | 0.51% |
| Return on Equity (TTM) | 4.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Packaged Foods (US) | Mixed | Mixed |
| Packaged Foods (Global) | Mixed | Mixed | |
| Stock | ChromaDex Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment. |
|
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Investment Style | Small Core |
| % Held by Insiders | 35.41% |
| % Held by Institutions | 24.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Winton Group Ltd | 30 Sep 2024 | 178,078 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Roth MKM, 34.68%) | Buy |
| 8.00 (HC Wainwright & Co., 34.68%) | Buy | |
| Median | 8.00 (34.68%) | |
| Average | 8.00 (34.68%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth MKM | 06 Nov 2024 | 8.00 (34.68%) | Buy | 6.99 |
| HC Wainwright & Co. | 04 Nov 2024 | 8.00 (34.68%) | Buy | 5.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2025 | Announcement | ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
| 03 Dec 2024 | Announcement | ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category |
| 14 Nov 2024 | Announcement | ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement |
| 07 Nov 2024 | Announcement | ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide |
| 31 Oct 2024 | Announcement | ChromaDex Corporation Reports Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |